Medication info

BONEJOA Injection (Ibandronic Acid Sodium Monohydrate)

Prescription medicationInjectionsIntravenous injection
Ingredient · strength
Ibandronate Sodium Monohydrate›3.375mg / 1 prefilled syringe
Manufacturer / importer
White Life Science Co., Ltd.
Appearance
The injection is a colorless, transparent solution contained in a colorless, transparent glass prefilled syringe, which comes with a single-use needle.
Packaging
3ml x 1 vial
Approval status
Active

MFDS item code 201700825 · Notified 2017.02.15 · Insurance code 625201711

Summary

Main use
Treatment of osteoporosis in postmenopausal women
Who receives it
Adults · Children
Adult administration
Inject 3mg intravenously over 15 - 30 seconds once every 3 months. Patients should also take calcium and vitamin D. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible and continue regular dosing at 3-month intervals thereafter. Patients with hepatic impairment: No dose adjustment is necessary. No dose adjustment is necessary for patients with mild or moderate renal impairment who have a serum creatinine of 200 µmol/L(2.3mg/dL) or lower or a creatinine clearance of 30ml/min or higher. Administration of this medicine is not recommended for patients with a serum creatinine exceeding 200 µmol/L(2.3mg/dL) or a creatinine clearance below 30ml/min, as clinical experience is insufficient. Elderly: No dose adjustment is necessary.
Child administration
Efficacy and safety in children 18 years of age or younger have not been studied.

Ingredients

Manufacturer
White Life Science Co., Ltd.

Efficacy & effects

Treatment of osteoporosis in postmenopausal women

  • Osteoporosis
View approved original text

This drug is used to treat osteoporosis that may occur in postmenopausal women. Osteoporosis is a condition where bones become weak and are at high risk of fractures. This drug helps increase bone density and reduce fracture risk, thus maintaining healthy bones. It effectively protects bone health in postmenopausal women and prevents fractures. Therefore, it is used for the treatment of postmenopausal osteoporosis.

How it is given

Adult administration

Inject 3mg intravenously over 15 - 30 seconds once every 3 months. Patients should also take calcium and vitamin D. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible and continue regular dosing at 3-month intervals thereafter. Patients with hepatic impairment: No dose adjustment is necessary. No dose adjustment is necessary for patients with mild or moderate renal impairment who have a serum creatinine of 200 µmol/L(2.3mg/dL) or lower or a creatinine clearance of 30ml/min or higher. Administration of this medicine is not recommended for patients with a serum creatinine exceeding 200 µmol/L(2.3mg/dL) or a creatinine clearance below 30ml/min, as clinical experience is insufficient. Elderly: No dose adjustment is necessary.

Child administration

Efficacy and safety in children 18 years of age or younger have not been studied.

Precautions

This drug must be administered as an intravenous injection, and caution should be exercised as improper administration around arteries or veins may cause tissue damage. It should not be used in patients with hypersensitivity to this drug or untreated hypocalcemia. During the use of this drug, gastrointestinal symptoms such as gastritis, diarrhea, abdominal pain, indigestion, nausea, and constipation may appear. Musculoskeletal symptoms such as myalgia, arthralgia, and musculoskeletal pain have also been reported. In some patients, influenza-like symptoms may occur, which include fever, chills, fatigue, and arthralgia, usually mild and temporary. Adverse effects related to the nervous system and skin, such as headache, rash, and fatigue, may also occur. Long-term use of this drug has been rarely associated with serious bone-related side effects such as osteonecrosis of the jaw or external auditory canal, thus oral hygiene and dental care should be prioritized. During osteoporosis treatment, muscle, joint, and bone pain may worsen; should these symptoms occur, consult with healthcare professionals. If pain in the thigh or groin is present, consider the possibility of atypical femoral fractures and further examination is needed. In cases of pregnancy or breastfeeding, the safety of this drug is not established and should be avoided. As this drug is excreted through the kidneys, patients with renal impairment need regular monitoring. In cases of overdose, there may be a burden on the kidneys and liver, requiring careful monitoring, and appropriate treatment is necessary if hypocalcemia occurs. This drug should not be mixed with solutions that contain calcium and must be administered only by intravenous injection. Do not reuse needles and syringes; safely dispose of them after use. While the potential for interaction with other drugs during the use of this drug is low, it is recommended to consult with a physician or pharmacist.

Side effects

Gastritis, diarrhea, abdominal pain, indigestion, nausea, constipation, musculoskeletal pain, joint pain, muscle pain, influenza-like illness, fatigue, headache, rash, bone pain, weakness, injection site reaction, phlebitis, thrombophlebitis, hypersensitivity reaction, angioedema, facial edema, swelling, hives, uveitis, episkleritis, scleritis, anaphylactic reaction, shock, asthma exacerbation, Stevens-Johnson syndrome, erythema multiforme, vesicular dermatitis, atypical subtrochanteric and iliac femoral fracture, atypical iliac fracture, osteonecrosis of the jaw and external auditory canal, dizziness, optic nerve atrophy, lower motor neuron lesions, tremor, unspecified gastrointestinal disorders, benign gastrointestinal neoplasm, toothache, hyperventilation, cough, dyspnea, laryngitis, vaginitis, menopausal symptoms, multiple organ failure, death, insomnia, anxiety, tinnitus, hearing loss, hypothyroidism, lipoma, ocular hemorrhage, heart failure, urinary disorders, hematuria, skin desquamation, acute renal failure

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a sealed container to prevent air or moisture from entering, ideally at room temperature between 1 degree and 30 degrees Celsius. This helps maintain the effectiveness of the drug and prevents deterioration.

Appearance and packaging

Appearance

The injection is a colorless, transparent solution contained in a colorless, transparent glass prefilled syringe, which comes with a single-use needle.

Package unit

3ml x 1 vial

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.